Literature DB >> 34059760

A practice of using five-colour chart to guide the control of COVID-19 and resumption of work in Zhejiang Province, China.

Fan He1, Xiaopeng Shang1, Feng Ling1, Zhiping Chen1, Tiehong Fu2, Junfen Lin1, Zhen Wang3.   

Abstract

Since the outbreak of COVID-19 in December 2019 in Wuhan, Zhejiang has become the province with the largest number of cases. The aim of this article is to present Zhejiang province's experience of establishing an accurate and smart control mechanism for epidemic prevention and control and resumption of work and production using a 'five-colour epidemic chart'. The number of confirmed cases, proportion of local cases, and occurrence of clustered outbreaks were used as evaluation indicators to calculate the county-level epidemic risk and were assigned different weight coefficients; the absence of cases for 3 and 7 consecutive days was used as the adjustment index. When the first chart was published on February 9, there were 1 very-high-risk, 12 high-risk, and 12 low-risk counties. Under the five-colour chart, Zhejiang began to adopt precise measures to prevent and control the epidemic and resume work and production. By February 24, the low-risk counties had expanded to 82, with no high-risk and very-high-risk counties. The epidemic situation in Zhejiang province has been effectively controlled. The experience of epidemic prevention and control in Zhejiang is worthy to be emulated and learned by other countries and regions.

Entities:  

Year:  2021        PMID: 34059760     DOI: 10.1038/s41598-021-90808-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  6 in total

1.  New Statin Use and Mortality in Older Veterans.

Authors:  Ali Ahmed; Wen-Chih Wu; Charles Faselis
Journal:  JAMA       Date:  2020-11-10       Impact factor: 56.272

2.  Pre-pandemic psychiatric disorders and risk of COVID-19: a UK Biobank cohort analysis.

Authors:  Huazhen Yang; Wenwen Chen; Yao Hu; Yilong Chen; Yu Zeng; Yajing Sun; Zhiye Ying; Junhui He; Yuanyuan Qu; Donghao Lu; Fang Fang; Unnur A Valdimarsdóttir; Huan Song
Journal:  Lancet Healthy Longev       Date:  2020-10-26

3.  SARS-CoV-2 (COVID-19): What Do We Know About Children? A Systematic Review.

Authors:  Nisha S Mehta; Oliver T Mytton; Edward W S Mullins; Tom A Fowler; Catherine L Falconer; Orla B Murphy; Claudia Langenberg; Wikum J P Jayatunga; Danielle H Eddy; Jonathan S Nguyen-Van-Tam
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

Review 4.  A review on how to do hematology consults during COVID-19 pandemic.

Authors:  Kamal Kant Sahu; Jan Cerny
Journal:  Blood Rev       Date:  2020-11-08       Impact factor: 8.250

5.  Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.

Authors:  Cheryl Keech; Gary Albert; Iksung Cho; Andreana Robertson; Patricia Reed; Susan Neal; Joyce S Plested; Mingzhu Zhu; Shane Cloney-Clark; Haixia Zhou; Gale Smith; Nita Patel; Matthew B Frieman; Robert E Haupt; James Logue; Marisa McGrath; Stuart Weston; Pedro A Piedra; Chinar Desai; Kathleen Callahan; Maggie Lewis; Patricia Price-Abbott; Neil Formica; Vivek Shinde; Louis Fries; Jason D Lickliter; Paul Griffin; Bethanie Wilkinson; Gregory M Glenn
Journal:  N Engl J Med       Date:  2020-09-02       Impact factor: 91.245

6.  Epidemiological parameters of COVID-19 and its implication for infectivity among patients in China, 1 January to 11 February 2020.

Authors:  Qing-Bin Lu; Yong Zhang; Ming-Jin Liu; Hai-Yang Zhang; Neda Jalali; An-Ran Zhang; Jia-Chen Li; Han Zhao; Qian-Qian Song; Tian-Shuo Zhao; Jing Zhao; Han-Yu Liu; Juan Du; Ai-Ying Teng; Zi-Wei Zhou; Shi-Xia Zhou; Tian-Le Che; Tao Wang; Tong Yang; Xiu-Gang Guan; Xue-Fang Peng; Yu-Na Wang; Yuan-Yuan Zhang; Shou-Ming Lv; Bao-Cheng Liu; Wen-Qiang Shi; Xiao-Ai Zhang; Xiao-Gang Duan; Wei Liu; Yang Yang; Li-Qun Fang
Journal:  Euro Surveill       Date:  2020-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.